Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying, like in the case of TransCode Therapeutics, Inc. (NASDAQ:RNAZ), it sends a ...
TransCode Therapeutics (RNAZ) Board of Directors has approved a 1-for-33 reverse stock split. The reverse stock split was approved by TransCode’s stockholders on November 22, 2024, and is intended to ...
Shares of TransCode (NASDAQ:RNAZ) plunged 20% in morning trading Friday after the company announced a public offering followed by news that it had until Jan. 22 to regain compliance with Nasdaq’s ...
Transcode Therapeutics, Inc. (RNAZ) stock has reached a 52-week low, trading at $1.7, marking a significant downturn for the biotech company. With a market capitalization of just $1.25 million, ...
Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...
Unlock your investing potential with TipRanks Premium - Now At 40% OFF! Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter TransCode Therapeutics ( (RNAZ)) has ...
BOSTON, Jan. 11, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results